|
1
|
Xie W, Wei L, Guo J, Guo H, Song X and
Sheng X: Physiological functions of Wilms' tumor 1-associating
protein and its role in tumourigenesis. J Cell Biochem. Feb
12–2019.(Epub ahead of print). doi: 10.1002/jcb.28402.
|
|
2
|
Cone EB, Dalton SS, Van Noord M, Tracy ET,
Rice HE and Routh JC: Biomarkers for Wilms tumor: A systematic
review. J Urol. 196:1530–1535. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chakumatha E, Weijers J, Banda K, Bailey
S, Molyneux E, Chagaluka G and Israels T: Outcome at the end of
treatment of patients with common and curable childhood cancer
types in Blantyre, Malawi. Pediatr Blood Cancer. 67:e283222020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fuchs J: Surgical concepts in the
treatment of Wilms tumor: An update. Urologe A. 54:1784–1791.
2015.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Su C, Huang R, Yu Z, Zheng J, Liu F, Liang
H and Mo Z: Myelin and lymphocyte protein serves as a prognostic
biomarker and is closely associated with the tumor microenvironment
in the nephroblastoma. Cancer Med. 11:1427–1438. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanehira M, Harada Y, Takata R, Shuin T,
Miki T, Fujioka T, Nakamura Y and Katagiri T: Involvement of
upregulation of DEPDC1 (DEP domain containing 1) in bladder
carcinogenesis. Oncogene. 26:6448–6455. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu Y, Sun L, Yu J, Xiang Y, Shen M, Wasan
HS, Ruan S and Qiu S: Identification of biomarkers in colon cancer
based on bioinformatic analysis. Transl Cancer Res. 9:4879–4895.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harada Y, Kanehira M, Fujisawa Y, Takata
R, Shuin T, Miki T, Fujioka T, Nakamura Y and Katagiri T:
Cell-permeable peptide DEPDC1-ZNF224 interferes with
transcriptional repression and oncogenicity in bladder cancer
cells. Cancer Res. 70:5829–5839. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li YY, Li W, Chang GZ and Li YM: Long
noncoding RNA KTN1 antisense RNA 1exerts an oncogenic function in
lung adenocarcinoma by regulating DEP domain containing 1
expression via activating epithelial-mesenchymal transition.
Anticancer Drugs. 32:614–625. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gong Z, Chu H, Chen J, Jiang L, Gong B,
Zhu P, Zhang C, Wang Z, Zhang W, Wang J, et al: DEPDC1 upregulation
promotes cell proliferation and predicts poor prognosis in patients
with gastric cancer. Cancer Biomark. 30:299–307. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo J, Zhou S, Huang P, Xu S, Zhang G, He
H, Zeng Y, Xu CX, Kim H and Tan Y: NNK-mediated upregulation of
DEPDC1 stimulates the progression of oral squamous cell carcinoma
by inhibiting CYP27B1 expression. Am J Cancer Res. 10:1745–1760.
2020.PubMed/NCBI
|
|
12
|
Wang Q, Jiang S, Liu J, Ma G, Zheng J and
Zhang Y: DEP domain containing 1 promotes proliferation, invasion,
and epithelial-mesenchymal transition in colorectal cancer by
enhancing expression of suppressor of zest 12. Cancer Biother
Radiopharm. 36:36–44. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo W, Li H, Liu H, Ma X, Yang S and Wang
Z: DEPDC1 drives hepatocellular carcinoma cell proliferation,
invasion and angiogenesis by regulating the CCL20/CCR6 signaling
pathway. Oncol Rep. 42:1075–1089. 2019.PubMed/NCBI
|
|
14
|
Zhao H, Yu M, Sui L, Gong B, Zhou B, Chen
J, Gong Z and Hao C: High expression of DEPDC1 promotes malignant
phenotypes of breast cancer cells and predicts poor prognosis in
patients with breast cancer. Front Oncol. 9:2622019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lam EW, Brosens JJ, Gomes AR and Koo CY:
Forkhead box proteins: Tuning forks for transcriptional harmony.
Nat Rev Cancer. 13:482–495. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gomes AR, Brosens JJ and Lam EW: Resist or
die: FOXO transcription factors determine the cellular response to
chemotherapy. Cell Cycle. 7:3133–3136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Farhan M, Wang H, Gaur U, Little PJ, Xu J
and Zheng W: FOXO signaling pathways as therapeutic targets in
cancer. Int J Biol Sci. 13:815–827. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calissi G, Lam EW and Link W: Therapeutic
strategies targeting FOXO transcription factors. Nat Rev Drug
Discov. 20:21–38. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen YH, Li CL, Chen WJ, Liu J and Wu HT:
Diverse roles of FOXO family members in gastric cancer. World J
Gastrointest Oncol. 13:1367–1382. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiramongkol Y and Lam EW: FOXO
transcription factor family in cancer and metastasis. Cancer
Metastasis Rev. 39:681–709. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yadav RK, Chauhan AS, Zhuang L and Gan B:
FoxO transcription factors in cancer metabolism. Semin Cancer Biol.
50:65–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin L, Zhang J, Fu HQ, Zhang X and Pan YL:
FOXO3a inhibits the EMT and metastasis of breast cancer by
regulating TWIST-1 mediated miR-10b/CADM2 axis. Transl Oncol.
14:1010962021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao H, Chen W, Zhu Y and Lou J: Hypoxia
promotes pancreatic cancer cell migration, invasion, and
epithelial-mesenchymal transition via modulating the
FOXO3a/DUSP6/ERK axis. J Gastrointest Oncol. 12:1691–1703. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding D, Ao X, Li M, Miao S, Liu Y, Lin Z,
Wang M, He Y and Wang J: FOXO3a-dependent Parkin regulates the
development of gastric cancer by targeting ATP-binding cassette
transporter E1. J Cell Physiol. 236:2740–2755. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qian C and Liu Q: FOXO3a inhibits
nephroblastoma cell proliferation, migration and invasion, and
induces apoptosis through downregulating the Wnt/β-catenin
signaling pathway. Mol Med Rep. 24:7962021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Tian Y, Zhong W, Wang N, Wang Y,
Zhang Y, Zhang Z, Li J, Ma F, Zhao Z and Peng Y: Artemisia argyi
essential oil inhibits hepatocellular carcinoma metastasis via
suppression of DEPDC1 dependent Wnt/β-catenin signaling pathway.
Front Cell Dev Biol. 9:6647912021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sharifi A, Vahedi H, Honarvar MR, Amiriani
T, Nikniaz Z, Rad EY and Hosseinzadeh-Attar MJ: Vitamin D decreases
CD40L gene expression in ulcerative colitis patients: A randomized,
double-blinded, placebo-controlled trial. Turk J Gastroenterol.
31:99–104. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Al-Hussain T, Ali A and Akhtar M: Wilms
tumor: An update. Adv Anat Pathol. 21:166–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cotton CA, Peterson S, Norkool PA,
Takashima J, Grigoriev Y, Green DM and Breslow NE: Early and late
mortality after diagnosis of wilms tumor. J Clin Oncol.
27:1304–1309. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang W, Li A, Han X, Wang Q, Guo J, Wu Y,
Wang C and Huang G: DEPDC1 up-regulates RAS expression to inhibit
autophagy in lung adenocarcinoma cells. J Cell Mol Med.
24:13303–13313. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou C, Wang P, Tu M, Huang Y, Xiong F and
Wu Y: DEPDC1 promotes cell proliferation and suppresses sensitivity
to chemotherapy in human hepatocellular carcinoma. Biosci Rep.
39:BSR201909462019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Obara W, Ohsawa R, Kanehira M, Takata R,
Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y and Fujioka
T: Cancer peptide vaccine therapy developed from oncoantigens
identified through genome-wide expression profile analysis for
bladder cancer. Jpn J Clin Oncol. 42:591–600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hao S, Tian W, Chen Y, Wang L, Jiang Y,
Gao B and Luo D: MicroRNA-374c-5p inhibits the development of
breast cancer through TATA-box binding protein associated factor
7-mediated transcriptional regulation of DEP domain containing 1. J
Cell Biochem. 120:15360–15368. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kassambara A, Schoenhals M, Moreaux J,
Veyrune JL, Rème T, Goldschmidt H, Hose D and Klein B: Inhibition
of DEPDC1A, a bad prognostic marker in multiple myeloma, delays
growth and induces mature plasma cell markers in malignant plasma
cells. PLoS One. 8:e627522013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tian C, Abudoureyimu M, Lin X, Chu X and
Wang R: Linc-ROR facilitates progression and angiogenesis of
hepatocellular carcinoma by modulating DEPDC1 expression. Cell
Death Dis. 12:10472021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng H, Li BH, Liu C, Jia L and Liu FT:
Comprehensive analysis of lncRNA-mediated ceRNA crosstalk and
identification of prognostic biomarkers in Wilms' tumor. Biomed Res
Int. 2020:49516922020.PubMed/NCBI
|
|
37
|
Shen J and Xi M: DEPDC1 is highly
expressed in lung adenocarcinoma and promotes tumor cell
proliferation. Zhongguo Fei Ai Za Zhi. 24:453–460. 2021.(In
Chinese). PubMed/NCBI
|
|
38
|
Liu Y, Ao X, Ding W, Ponnusamy M, Wu W,
Hao X, Yu W, Wang Y, Li P and Wang J: Critical role of FOXO3a in
carcinogenesis. Mol Cancer. 17:1042018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen YF, Pandey S, Day CH, Chen YF, Jiang
AZ, Ho TJ, Chen RJ, Padma VV, Kuo WW and Huang CY: Synergistic
effect of HIF-1α and FoxO3a trigger cardiomyocyte apoptosis under
hyperglycemic ischemia condition. J Cell Physiol. 233:3660–3671.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Joseph J, Ametepe ES, Haribabu N, Agbayani
G, Krishnan L, Blais A and Sad S: Inhibition of ROS and
upregulation of inflammatory cytokines by FoxO3a promotes survival
against Salmonella typhimurium. Nat Commun. 7:127482016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fluteau A, Ince PG, Minett T, Matthews FE,
Brayne C, Garwood CJ, Ratcliffe LE, Morgan S, Heath PR, Shaw PJ, et
al: The nuclear retention of transcription factor FOXO3a correlates
with a DNA damage response and increased glutamine synthetase
expression by astrocytes suggesting a neuroprotective role in the
ageing brain. Neurosci Lett. 609:11–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM,
Li PC, Lin SH and Hu MC: Forkhead box transcription factor FOXO3a
suppresses estrogen-dependent breast cancer cell proliferation and
tumorigenesis. Breast Cancer Res. 10:R212018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Y and Wang X: Targeting the
Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol.
13:1652020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ashihara E, Takada T and Maekawa T:
Targeting the canonical Wnt/β-catenin pathway in hematological
malignancies. Cancer Sci. 106:665–671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hu Z, Li L, Cheng P, Liu Q, Zheng X, Peng
F and Zhang Q: lncRNA MSC-AS1 activates Wnt/β-catenin signaling
pathway to modulate cell proliferation and migration in kidney
renal clear cell carcinoma via miR-3924/WNT5A. J Cell Biochem.
121:4085–4093. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou J, Toh SH, Chan ZL, Quah JY, Chooi
JY, Tan TZ, Chong PSY, Zeng Q and Chng WJ: A loss-of-function
genetic screening reveals synergistic targeting of AKT/mTOR and
WTN/β-catenin pathways for treatment of AML with high PRL-3
phosphatase. J Hematol Oncol. 11:362018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Qu D, Cui F, Lu D, Yang Y and Xu Y: DEP
domain containing 1 predicts prognosis of hepatocellular carcinoma
patients and regulates tumor proliferation and metastasis. Cancer
Sci. 110:157–165. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu H, Song Y, Qiu H, Liu Y, Luo K, Yi Y,
Jiang G, Lu M, Zhang Z, Yin J, et al: Downregulation of FOXO3a by
DNMT1 promotes breast cancer stem cell properties and
tumorigenesis. Cell Death Differ. 27:966–983. 2020. View Article : Google Scholar : PubMed/NCBI
|
